Literature DB >> 8640806

Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma.

D J Marsh1, S D Andrew, C Eng, D L Learoyd, A G Capes, R Pojer, A L Richardson, C Houghton, L M Mulligan, B A Ponder, B G Robinson.   

Abstract

Inherited cancer syndromes predispose an individual to development of specific tumors. Somatic and germline mutations in the same tumor suppressor gene, as described in Knudson's two-mutation model, are well recognized. Inherited mutations in the RET proto-oncogene, which encodes a receptor tyrosine kinase, predispose individuals to the multiple endocrine neoplasia type 2 (MEN 2) cancer syndromes. The major component tumor of these syndromes is medullary thyroid carcinoma (MTC). To date, somatic mutations in RET have not been identified in tumors from individuals with MEN 2, although they have been well documented in sporadic MEN 2-related tumors. We have identified, among 16 MEN 2 cases with well-defined RET germline mutations, a somatic missense mutation at codon 918 of RET in 3 of 15 MTCs and in a sample with hyperplastic C-cells (presumed precursor to hereditary MTC). We suggest that the presence of a somatic mutation, in addition to the preexisting germline mutation in hereditary MTCs, may contribute to tumorigenesis in vivo.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8640806

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

Review 1.  Molecular mechanisms of RET activation in human neoplasia.

Authors:  M Santoro; F Carlomagno; R M Melillo; M Billaud; G Vecchio; A Fusco
Journal:  J Endocrinol Invest       Date:  1999-11       Impact factor: 4.256

2.  Does a somatic deletion in RET clarify the sporadic nature of medullary thyroid carcinoma?

Authors:  O Gimm; D J Marsh
Journal:  J Endocrinol Invest       Date:  2003-04       Impact factor: 4.256

3.  Various penetrance of familial medullary thyroid carcinoma in patients with RET protooncogene codon 790/791 germline mutations.

Authors:  Guido Fitze; Mandy Schierz; Jan Bredow; Hans D Saeger; Dietmar Roesner; Hans K Schackert
Journal:  Ann Surg       Date:  2002-11       Impact factor: 12.969

Review 4.  Molecular genetics of thyroid cancer.

Authors:  Maha Rebaї; Ahmed Rebaї
Journal:  Genet Res (Camb)       Date:  2016-05-13       Impact factor: 1.588

Review 5.  Molecular pathogenesis of MEN2-associated tumors.

Authors:  Christian A Koch
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

6.  Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation.

Authors:  F M Michiels; S Chappuis; B Caillou; A Pasini; M Talbot; R Monier; G M Lenoir; J Feunteun; M Billaud
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

7.  Large-scale analysis of mutations in RET exon 16 in sporadic medullary thyroid carcinomas in Japan.

Authors:  T Takano; A Miyauchi; H Yoshida; Y Hasegawa; K Kuma; N Amino
Journal:  Jpn J Cancer Res       Date:  2001-06

8.  Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.

Authors:  Andreas M Heilmann; Vivek Subbiah; Kai Wang; James X Sun; Julia A Elvin; Juliann Chmielecki; Steven I Sherman; Ravi Murthy; Naifa L Busaidy; Ishwaria Subbiah; Roman Yelensky; Chaitali Nangia; Jo-Anne Vergilio; Saad A Khan; Rachel L Erlich; Doron Lipson; Jeffrey S Ross; Vincent A Miller; Manisha H Shah; Siraj M Ali; Philip J Stephens
Journal:  Oncology       Date:  2016-05-21       Impact factor: 2.935

Review 9.  RET codon 609 mutations: a contribution for better clinical managing.

Authors:  Caterina Mian; Paola Sartorato; Susi Barollo; Mariangela Zane; Giuseppe Opocher
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

10.  Germline Mutation of the CCK Receptor: A Novel Biomarker for Pancreas Cancer.

Authors:  Jelal Alsubai; Gail L Matters; Christopher O McGovern; Jiangang Liao; Evan L Gilius; Jill P Smith
Journal:  Clin Transl Gastroenterol       Date:  2016-01-07       Impact factor: 4.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.